TMPRSS2 and COVID-19: In contrast to enhanced levels of TMPRSS2, T2 inflammation, whether observed in vivo or induced with IL-13 stimulation, precipitated a marked reduction in levels of epithelial ACE2, thus making it difficult to predict how T2 inflammation might affect overall risk for a poor COVID-19 outcome.